Sept 1 (Reuters) – NOVARTIS AG: * NOVARTIS REMIBRUTINIB, A HIGH-EFFICACY ORAL BTK INHIBITOR, SIGNIFICANTLY REDUCES RELAPSE RATES AND SHOWS FAVORABLE SAFETY PROFILE IN PHASE III RMS TRIALS * REMODEL-1/
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)